BIOMAT Database Logo BIOMAT Database Logo

Design, synthesis, and evaluation of biphenyl-4-yl-acrylohydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors. 2009

Sabrina Dallavalle, and Raffaella Cincinelli, and Raffaella Nannei, and Lucio Merlini, and Gabriella Morini, and Sergio Penco, and Claudio Pisano, and Loredana Vesci, and Marcella Barbarino, and Valentina Zuco, and Michelandrea De Cesare, and Franco Zunino
Dipartimento di Scienze Molecolari Agroalimentari, Università di Milano, Via Celoria 2, 20133 Milano, Italy.

A series of hydroxamic acid-based histone deacetylase (HDAC) inhibitors were designed on the basis of a model of the HDAC2 binding site and synthesized. They are characterized by a cinnamic spacer, capped with a substituted phenyl group. Modifications of the spacer are also reported. In an in vitro assay with the isoenzyme HDAC2, a good correlation of the activity with the docking energy was found. In human ovarian carcinoma IGROV-1 cells, selected compounds produced significant acetylation of p53 and alpha-tubulin. Most compounds showed an antiproliferative activity comparable to that of SAHA. At equitoxic concentrations, the tested compounds were more effective than SAHA in inducing apoptotic cell death. Compounds selected for in vivo evaluation exhibited a significant antitumor activity on three tumor models at well tolerated doses, thus suggesting a good therapeutic index.

UI MeSH Term Description Entries
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D004791 Enzyme Inhibitors Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. Enzyme Inhibitor,Inhibitor, Enzyme,Inhibitors, Enzyme
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006877 Hydroxamic Acids A class of weak acids with the general formula R-CONHOH. Hydroxamic Acid,Acid, Hydroxamic,Acids, Hydroxamic
D000107 Acetylation Formation of an acetyl derivative. (Stedman, 25th ed) Acetylations
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D014404 Tubulin A microtubule subunit protein found in large quantities in mammalian brain. It has also been isolated from SPERM FLAGELLUM; CILIA; and other sources. Structurally, the protein is a dimer with a molecular weight of approximately 120,000 and a sedimentation coefficient of 5.8S. It binds to COLCHICINE; VINCRISTINE; and VINBLASTINE. alpha-Tubulin,beta-Tubulin,delta-Tubulin,epsilon-Tubulin,gamma-Tubulin,alpha Tubulin,beta Tubulin,delta Tubulin,epsilon Tubulin,gamma Tubulin
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs

Related Publications

Sabrina Dallavalle, and Raffaella Cincinelli, and Raffaella Nannei, and Lucio Merlini, and Gabriella Morini, and Sergio Penco, and Claudio Pisano, and Loredana Vesci, and Marcella Barbarino, and Valentina Zuco, and Michelandrea De Cesare, and Franco Zunino
Design, synthesis, and evaluation of isoindolinone-hydroxamic acid derivatives as histone deacetylase (HDAC) inhibitors.
September 2007, Bioorganic & medicinal chemistry letters,
Sabrina Dallavalle, and Raffaella Cincinelli, and Raffaella Nannei, and Lucio Merlini, and Gabriella Morini, and Sergio Penco, and Claudio Pisano, and Loredana Vesci, and Marcella Barbarino, and Valentina Zuco, and Michelandrea De Cesare, and Franco Zunino
Design, synthesis and biological evaluation of 4-piperidin-4-yl-triazole derivatives as novel histone deacetylase inhibitors.
May 2019, Bioscience trends,
Sabrina Dallavalle, and Raffaella Cincinelli, and Raffaella Nannei, and Lucio Merlini, and Gabriella Morini, and Sergio Penco, and Claudio Pisano, and Loredana Vesci, and Marcella Barbarino, and Valentina Zuco, and Michelandrea De Cesare, and Franco Zunino
Design, synthesis and biological evaluation of thienopyrimidine hydroxamic acid based derivatives as structurally novel histone deacetylase (HDAC) inhibitors.
March 2017, European journal of medicinal chemistry,
Sabrina Dallavalle, and Raffaella Cincinelli, and Raffaella Nannei, and Lucio Merlini, and Gabriella Morini, and Sergio Penco, and Claudio Pisano, and Loredana Vesci, and Marcella Barbarino, and Valentina Zuco, and Michelandrea De Cesare, and Franco Zunino
Design, synthesis, and evaluation of cyclic amide/imide-bearing hydroxamic acid derivatives as class-selective histone deacetylase (HDAC) inhibitors.
November 2006, Bioorganic & medicinal chemistry,
Sabrina Dallavalle, and Raffaella Cincinelli, and Raffaella Nannei, and Lucio Merlini, and Gabriella Morini, and Sergio Penco, and Claudio Pisano, and Loredana Vesci, and Marcella Barbarino, and Valentina Zuco, and Michelandrea De Cesare, and Franco Zunino
Design, synthesis and preliminary bioactivity evaluations of substituted quinoline hydroxamic acid derivatives as novel histone deacetylase (HDAC) inhibitors.
August 2015, Bioorganic & medicinal chemistry,
Sabrina Dallavalle, and Raffaella Cincinelli, and Raffaella Nannei, and Lucio Merlini, and Gabriella Morini, and Sergio Penco, and Claudio Pisano, and Loredana Vesci, and Marcella Barbarino, and Valentina Zuco, and Michelandrea De Cesare, and Franco Zunino
Design, synthesis and biological evaluation of novel thioquinazolinone-based 2-aminobenzamide derivatives as potent histone deacetylase (HDAC) inhibitors.
July 2019, European journal of medicinal chemistry,
Sabrina Dallavalle, and Raffaella Cincinelli, and Raffaella Nannei, and Lucio Merlini, and Gabriella Morini, and Sergio Penco, and Claudio Pisano, and Loredana Vesci, and Marcella Barbarino, and Valentina Zuco, and Michelandrea De Cesare, and Franco Zunino
Design, synthesis, and biological evaluation of indole-based hydroxamic acid derivatives as histone deacetylase inhibitors.
January 2022, European journal of medicinal chemistry,
Sabrina Dallavalle, and Raffaella Cincinelli, and Raffaella Nannei, and Lucio Merlini, and Gabriella Morini, and Sergio Penco, and Claudio Pisano, and Loredana Vesci, and Marcella Barbarino, and Valentina Zuco, and Michelandrea De Cesare, and Franco Zunino
Discovery, synthesis, and pharmacological evaluation of spiropiperidine hydroxamic acid based derivatives as structurally novel histone deacetylase (HDAC) inhibitors.
April 2011, Journal of medicinal chemistry,
Sabrina Dallavalle, and Raffaella Cincinelli, and Raffaella Nannei, and Lucio Merlini, and Gabriella Morini, and Sergio Penco, and Claudio Pisano, and Loredana Vesci, and Marcella Barbarino, and Valentina Zuco, and Michelandrea De Cesare, and Franco Zunino
Design, Synthesis and Biological Evaluation of Novel Coumarin-Based Hydroxamate Derivatives as Histone Deacetylase (Hdac) Inhibitors with Antitumor Activities.
July 2019, Molecules (Basel, Switzerland),
Sabrina Dallavalle, and Raffaella Cincinelli, and Raffaella Nannei, and Lucio Merlini, and Gabriella Morini, and Sergio Penco, and Claudio Pisano, and Loredana Vesci, and Marcella Barbarino, and Valentina Zuco, and Michelandrea De Cesare, and Franco Zunino
Design, synthesis and biological evaluation of 4-anilinothieno[2,3-d]pyrimidine-based hydroxamic acid derivatives as novel histone deacetylase inhibitors.
November 2014, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!